聯盛化學(301212.SZ):52.6萬噸/年電子和專用化學品改建項目(一期)已於7月開工建設
格隆匯12月7日丨聯盛化學(301212.SZ)近期在接待機構投資者調研時表示,截至2023年6月底,公司的超純電子化學品及生物可降解新材料等新建項目(一期)投資進度為55.44%,目前相關辦公樓、研發檢測大樓、車間及公用工程基建主體基本完工,預計春節前後開始設備安裝。公司的52.6萬噸/年電子和專用化學品改建項目(一期)已於2022年7月開工建設,目前綜合辦公樓、研發化驗樓、中央控制樓、車間和公用工程等主體工程基建正同時施工中。截至2023年4月17日,公司董事會已累計審議通過向募投項目“52.6萬噸/年電子和專用化學品改建項目(一期)”增資2個億。公司正按計劃有序推進募投項目建設,爭取早日建成投產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.